TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05126303
Drug: RMC-035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for Solution for Infusion
Study: NCT05126303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for Solution for Infusion
Study: NCT04817189
Drug: NEPA (300mg netupitant/0.5mg palonosetron)
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.
Study: NCT04565288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo (sugar pill)
Study: NCT05701826
Drug: HRS3797
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS3797 for injection, low dose
Study: NCT05701826
Drug: HRS3797
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS3797 for injection, medium dose
Study: NCT05701826
Drug: HRS3797
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS3797 for injection, high dose
Study: NCT00684385
Drug: ZD1839
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mg administered daily for patients with NSCLC and500mg daily for patients with H\&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H\&NC will take two tablets at each dose administration.
Study: NCT05276856
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step 1:~* Reduce the dose of T4 therapy by 50% and recheck serum T4 after 2 weeks.~* If serum T4 is normal, go to step 2.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 2:~* Discontinue T4 therapy altogether and recheck serum TSH and T4 after 2 weeks.~* If serum T4 is normal, go to step 3.~* If serum T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).~Step 3:~* Recheck serum TSH and T4 after 8 weeks.~* If serum TSH and T4 levels are normal, these patients will be regarded as having successful T4 withdrawal.~* If T4 drops to below normal then resume full T4 replacement (these patients will be considered as having withdrawal failure).
Study: NCT04669067
Drug: KRT-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
Study: NCT04641351
Drug: Zilretta Injectable Product or Placebo
Normalized name: Zilretta Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The purpose of this intervention is to determine the use of extended release steroid knee injection (Zilretta) at the end of the surgery and its effects on your knee pain.In this study Zilretta will be injected intra-operatively for your arthroscopic partial meniscectomy (APM) surgery.Participants will have MRIs x-rays, and provide a sample of the synovial fluid from both knees at the beginning of surgery. This fluid is drained at the beginning of surgery and then usually discarded. Three samples each of blood and urine will be collected over the study period from each participant and sample of joint (synovial tissue) taken. Participants will be asked to answer questions about knee pain.
Study: NCT05077423
Drug: CD33*CD3 BsAb
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD33xCD3 is a bispecific monoclonal antibody, which specifically targets CD33 on the AML blasts and CD3 on the T cells
Study: NCT04820023
Drug: BBT-176
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BBT-176 given orally alone
Study: NCT06546527
Drug: [177Lu]Lu-PSMA-137
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[177Lu\]Lu-PSMA-137 500 MBq;50% optimal dosing;100% optimal dosing
Study: NCT04602845
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50ug Fentanyl intravenously
Study: NCT04602845
Drug: Flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg Fentanyl intravenously
Study: NCT06089603
Drug: Conventional pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment of the patient
Study: NCT05775250
Drug: giomer varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giomer varnish containing surface pre-reacted glass-ionomer (PRG) filler, will be administrated once.
Study: NCT06363292
Drug: PRO-231
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 0.5% Ophthalmic solution.
Study: NCT06363292
Drug: VIGAMOXI®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 0.5% Ophthalmic solution.
Study: NCT05809700
Drug: Freshly manufactured 35 kDa hyaluronan fragment
Normalized name: PALMITOYL FRAGMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: This mixture of high molecular weight HA and hyaluronidase containing 100 mg of HA was locally injected at the pain point or where the nerve trunk innervates the pain point. Then, the pain scale (NPRS) was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.~Each time, according to the amount of high molecular weight HA containing 100 mg HA and hyaluronidase mixture, the pain point area and pain point area of the nerve trunk innervation of the local multipoint injection. Then, the pain scale was used to evaluate pain, and the pain relief of patients before and after treatment was recorded.
Study: NCT05872412
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV bolus on day 1 every three weeks for four cycles.
Study: NCT05872412
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV over 1 hour on day 1 every three weeks for four cycles.
Study: NCT05332704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Part A: Single ascending doses of placebo as a single IV dose (Cohort A1-A5).
Study: NCT05332704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Part B: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort B1 and B2).
Study: NCT05332704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Part C: Multiple doses of placebo as IV doses over a 4-week treatment period (Cohort C1 and C2).
Study: NCT06564753
Drug: Drug: Placebo daily and orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: • Placebo comparator
Study: NCT06564753
Drug: NA-931, dose 1, daily and orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NA-931 dose 1, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist
Study: NCT06564753
Drug: NA-931, dose2, daily and orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NA-931 dose 2, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist
Study: NCT06564753
Drug: NA-931 dose 3, daily and orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NA-931 dose 3, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist
Study: NCT06564753
Drug: NA-931 dose 4, daily and orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NA-931 dose 4, daily and orally~• NA-931 is a peptide quadruple GLP-1, IGF-1, GIP , Glucagon quadruple agonist
Study: NCT05913674
Drug: Modified early post-operative intraperitoneal chemotherapy (mEPIC)
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: On post-operative days 1 and 2, an abdominal reservoir is obtained by administering 1000 mL of plasmalyte with 50 mEq NaHCO3 via a Tenckhoff catheter. Participants will then receive an intraperitoneal fluorouracil bolus of 400 mg/m2 administered over 1 to 2 minutes followed by a continuous intraperitoneal fluorouracil infusion of 1200 mg/m2 over the next 24 hours. During the continuous intraperitoneal infusion of fluorouracil, 50 mg of folinic acid is administered intravenously.~After completion of mEPIC day 1, the perfusate is drained out before starting mEPIC day 2.
Study: NCT06151483
Drug: Alpha-Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT06634069
Drug: 3% NaCl
Normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: active compartor 3% NaCl
Study: NCT04767321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel will be applied topically to both nostrils by a qualified health professional. On each dosing occasion, a large drop of IMP will be applied into each nostril and distributed to cover the whole area of the nostril.
Study: NCT06304857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet matching dapagliflozin 10 mg q.d
Study: NCT04840511
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 0.15 ml bolus followed by 0.2 ml/kg/hr during operation and 0.1 ml/kg/hr during postoperative 24 hours
Study: NCT05586373
Drug: medication 1
Normalized name: Acne Medication 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen pills, identical to the intervention (dipyrone pills), will be administered every 6 hour for a maximum of five days
Study: NCT05586373
Drug: medication 2
Normalized name: clearproof acne medication 2 % Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone pills, identical to the intervention (ibuprofen pills), will be administered every 6 hour for a maximum of five days
Study: NCT05606107
Drug: Glucocorticoid
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid
Study: NCT05081219
Drug: Placebo (Insulin Diluent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will administer placebo (insulin diluent) four times per day with an intranasal delivery device.
Study: NCT05508347
Drug: Nituzumab/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group: 3 cycles of induction chemotherapy combined with 9 times of nituzumab targeted therapy followed by 2-3 cycles of synchronous radiotherapy and chemotherapy combined with 7 times of nituzumab targeted therapy, a total of 16 times of nituzumab targeted therapy, equivalent to the whole course targeted therapy.~Control group: 3 cycles of induction chemotherapy combined with 9 times of placebo treatment followed by 2-3 cycles of concurrent chemoradiotherapy combined with 7 times of nituzumab targeted therapy, a total of 7 times of nituzumab targeted therapy, only targeted therapy during concurrent chemoradiotherapy
Study: NCT06638502
Drug: HRX215 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRX215 capsules 250 mg orally twice daily
Study: NCT06638502
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules matching appearance of HRX215
Study: NCT04722666
Drug: MIJ821 Intravenous Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIJ821 supplied in vials to be prepared on a mg/kg basis and to be administered for 40 minutes IV infusion on Day 1, Day 15 and Day 29
Study: NCT04722666
Drug: Placebo Intravenous Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 minutes IV infusion of 0.9% sodium chloride solution on Day1, Day 15 and Day 29
Study: NCT06301373
Drug: Methotrexate Combined With Tofacitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate Combined With Tofacitinib
Study: NCT06301373
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate
Study: NCT05849766
Drug: Ramipril Tritace®, Carvedilol Carvid®,and Spironolactone Aldactone®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg once daily, carvedilol 6.25 mg twice daily and spironolactone 25 once daily
Study: NCT06640738
Drug: arm 2
Normalized name: Surgitube Arm 2 5/8x50"
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study tries to find the best drug concentration of Remifentanil, ALVOGEN® (2 mg/vial) in Uterine Fibroid Ablation. We have two arms. Arm 1 with Remifentanil, ALVOGEN® (2 mg/vial) 1.0 ng/mL, and arm 2 with Remifentanil, ALVOGEN® (2 mg/vial) 2.0 ng/mL, both given via a syringe infusion pump, Perfusor® Space \| B. Braun.
Study: NCT05878704
Drug: GBT021601
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06634524
Drug: Dexmeditomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will receive IV infusion of (0.2 µg/kg/hr dexmeditomidine).
Study: NCT06634524
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will receive IV infusion of normal saline, at the same rate of dexmedetomidine infusion.
Study: NCT04656561
Drug: ANX007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: solution for injection; Route of Administration: IVT
Study: NCT06564857
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Age \< 70 years: Bolus of 4 μg/kg Ideal Body Weight remifentanil at anaesthesia induction; Age \>= 70 years: Bolus of 2 μg/kg ideal Body Weight remifentanil at anaesthesia induction
Study: NCT05337566
Drug: Azithromycin Pill + Cefuroxime
Normalized name: cefuroxime Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg (2 tablets) per orally when arriving to the hospital before the operation and a single dose Cefuroxime 1.5g (when body mass index is under 30) or 3g (for those whose body mass index is 30 or more) in the operating theatre before the incision
Study: NCT06565273
Drug: FBL-MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered an initial dose of FBL-MTX by subcutaneous route. Subsequent doses will be titrated according to clinical response. Maximum dosage will be 2.5 mg, every 2 weeks.
Study: NCT05121350
Drug: Arotinib hydrochloride capsule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of Anlotinib hydrochloride capsule
Study: NCT06467409
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient-controlled analgesia(PCA) administration
Study: NCT06467409
Drug: LPM3480392 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient-controlled analgesia(PCA) administration
Study: NCT06642077
Drug: LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 2 ampoules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml were injected into the sternotomy incision site and around the chest tubes of 30 patients in the experimental group. The total number and dose of opioids, the total number and dose of analgesics used to relieve the pain of the patients in the 24 hours after the injection of 2 ampules of LIDOFAST 40 mg/2 ml + 0.025 mg/2 ml, and the total number and dose of analgesics were recorded, and the patients were interviewed face-to-face 24 hours later, and PoRI was recorded. No intervention was performed on 30 patients in the control group, and standard treatment and care continued to be applied to these patients.
Study: NCT06645197
Drug: SNUG01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adeno-associated virus serotype 9 capsid containing human SG001 expression cassette
Study: NCT04899687
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20mg (or previously prescribed dose) will be taken once daily by mouth for 8 weeks
Study: NCT05432167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take placebo tablets by mouth once daily.
Study: NCT05040776
Drug: EP-7041 Injection
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-7041 infusion
Study: NCT04942002
Drug: Methylprednisolone Acetate 40 MG/ML [Depo-Medrol]
Normalized name: methylPREDNISolone acetate 40 MG/ML [DEPO-Medrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection performed by care provider
Study: NCT04942002
Drug: Placebo Comparator: Standard treatment + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Methylprednisolone succinate (1 g daily for 5 days) + paraocular injection of 0.9% saline solution by care provider
Study: NCT04991948
Drug: CYAD-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells
Study: NCT04991948
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU, leucovorin and oxaliplatin
Study: NCT05157360
Drug: HAT
Normalized name: KHAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT
Study: NCT05157360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline solution
Study: NCT05938608
Drug: Regimen 1 (Oral primaquine)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 15 mg base orally once
Study: NCT05938608
Drug: Regimen 2 (IV primaquine phosphate)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 7.5 mg base in normal saline 500 mL infused over 30 minutes intravenously
Study: NCT05938608
Drug: Regimen 3 (IV carboxyprimaquine)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxyprimaquine 7.93 mg base in normal saline 500 mL infused over 30 minutes intravenously
Study: NCT05294887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05849558
Drug: Ursoplus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg)
Study: NCT04624984
Drug: PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 Inhibitor, intravenous drip, d1; Gemcitabine, 1000mg/m2, intravenous drip, d1,d8; Vinorelbine, 50mg/m2, PO, d1,d8; Doxorubicin Liposome, 30mg/m2, intravenous drip, d1;
Study: NCT04882228
Drug: Entelon Tab.150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 8 weeks
Study: NCT04882228
Drug: Venitol Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 8 weeks
Study: NCT04882228
Drug: Placebo of Venitol Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 8 weeks (with Entelon Tab.150mg. It is for the masking.)
Study: NCT04882228
Drug: Placebo of Entelon Tab.150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily for 8 weeks(with Venitol Tab. It is for the masking.)
Study: NCT04906694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluent solution
Study: NCT04696029
Drug: Difluoromethylornithine
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFMO (difluoromethylornithine is an inhibitor of ornithine decarboxylase (ODC) designated chemically as 2-(difluoromethyl)-DL-ornithine monohydrochloride monohydrate.~The dosage form to be used in this study is provided as a convex tablet containing 192 mg eflornithine (equivalent to 250 mg of eflornithine HCl, monohydrate). The tablets are packaged and sealed in opaque white HDPE bottles, and each bottle contains 100 tablets. The DMFO tablets are supplied by USWorldMeds (USWM).~The tablets are to be stored at room temperature (20-250C).
Study: NCT04760691
Drug: Truvada plus Estradiol 1 mg
Normalized name: Truvada
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily
Study: NCT06451588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo treatment will be prepared based on the patients' fecal samples (autologous).
Study: NCT04518137
Drug: ATG-008 30 mg, orally, QD, each 4 week (28-day) a cycle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 patients enrolled will be treated with 30mg QD of ATG-008, orally, each 4 week (28-day) a cycle
Study: NCT06341894
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant/AI
Study: NCT05124730
Drug: Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of Reference (R) Product was administered orally with 240 mL of water.
Study: NCT05586776
Drug: Placebo Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
Study: NCT06179537
Drug: BLU-5937
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple doses assessment
Study: NCT06511778
Drug: Hemoblast Bellows application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoblast bellows is a hemostatic agent clinically proven effective on the validated SPOT GRADE scale for minimal, mild, and moderate bleeding. Patients will have the Hemoblast bellows applied during on pump sternotomy surgery.
Study: NCT06172140
Drug: Ciprofol group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients received 5 μ g of sufentanil 1 minute before intravenous infusion of ciprofol, followed by intravenous injection of ciprofol (0.4mg/kg). When the MOAA/S score is ≤ 1, vaginal disinfection begins. During the induction of sedation, the MOAA/S score is evaluated every 30 seconds. If the MOAA/S score remains above 1, a supplementary dose of 1/2 of the initial dose is injected within 10 seconds. During the maintenance phase, supplementary doses are given when there are signs of physical activity, eye opening, or speech. If more than 5 additional doses are required within 15 minutes, painless hysteroscopy is considered a failure, and propofol is immediately used to enhance sedation.
Study: NCT05656040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered subcutaneously
Study: NCT05803785
Drug: BBC1501
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBC1501 solution for Intravitreal injection
Study: NCT04466007
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,9% physiological saline
Study: NCT04277247
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline placebo injection
Study: NCT05014568
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied topically once daily
Study: NCT04760691
Drug: Truvada plus Estradiol 6 mg
Normalized name: Truvada
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily
Study: NCT04760691
Drug: Estradiol 6 mg alone
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol 3 mg by mouth twice daily